ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

Committee Unblinds Phase III Zytiga Study

March 30, 2012

NCI Workshop Summary “Incomplete,” Kopans Writes In Letter

April 16, 1993

BMS Award Honors Jordan; Matthews Media Wins $23 Million Contract From MCI.

April 6, 2001

Two Workshops To Look For New Research Areas

October 29, 1976

In Brief: WHO Begins Project To Urge Governments To Establish “National Cancer Programs”

October 30, 1998

NCI-Approved Clinical Trials

October 27, 2006